Ariad announces updated Phase I/II results on brigatinib

17 April 2015

Ariad Pharmaceuticals (Nasdaq: ARIA) has announced updated Phase I/II clinical data on its investigational tyrosine kinase inhibitor brigatinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.

The results show robust anti-tumor activity of brigatinib in patients with crizotinib-resistant ALK+ non-small cell lung cancer in 98 patients treated at doses of 90 mg/day for one week followed by escalation to 180 mg/day in the Phase II portion. These responses are now approaching one year.

Of the 79 ALK+ non-small cell lung cancer patients in the trial, 49 of them also had intracranial CNS metastases at baseline. The effect on the metastases was evaluated separately, and this review showed that 16 had measurable intracranial metastases and 33 had non-measurable metastases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK